Net revenue increases to $5.76 billion for Allergan’s second quarter

Allergan reported a 116% increase in net revenue to 5.76 billion for the second quarter 2015, compared with $2.67 billion in the second quarter 2014.

Diluted non-GAAP earnings per share increased 29% to $4.41 for the second quarter 2015 compared to $3.42 in the second quarter 2014, according to the press release.

Allergan reported a GAAP loss per share of $0.80 compared to GAAP income per diluted share of $0.28 in the prior year second quarter.

The acquisitions of Kythera, Oculeve and Naurex will strengthen the company’s aesthetics, eye care and central nervous system portfolios, according to Brent Saunders, CEO and President of Allergan.

For the second quarter 2015, non-GAAP gross margin was 72.3% compared with 56.3 during the same period in 2014.

Second quarter Botox revenues were $632 million.

Fillers’ revenues in the second quarter of 2015 were $196 million, reflecting the international performance of Juvéderm /Voluma product lines.

Source: www.allergan.com